Tirzepatide
Dual GIP/GLP-1 agonist with strong obesity trial data and FDA approval for chronic weight management.
View medication pageTherapy Hub
Weight Management
Weight management therapies aim to improve appetite regulation, caloric intake, and long-term metabolic outcomes through evidence-based pharmacology. This category emphasizes compounds with the strongest direct data in obesity treatment while also identifying agents such as oxytocin that have emerging but still early evidence around appetite, reward, and adiposity.
Available Medications
Each medication below is grouped here because its mechanism, clinical use, or published literature helps explain why it fits this therapy category.
Semaglutide
GLP-1 receptor agonist with robust obesity data and FDA approval for chronic weight management.
View medication pageOxytocin
Early and heterogeneous literature suggests possible effects on appetite, food intake, and adiposity, but this remains investigational.
View medication pageMore Medications Available
This is not a comprehensive list of our available medications. We have what you need.
Contact us for moreReferences
Studies, data, and supporting evidence
These references support the positioning statements used on this therapy hub. They are intended as educational source material for patients and prescribers, not as a substitute for individualized medical judgment.
FDA Approves New Medication for Chronic Weight Management
Official FDA announcement confirming tirzepatide's approval for chronic weight management in adults with obesity or overweight plus a weight-related condition.
Full Text →Tirzepatide Once Weekly for the Treatment of Obesity
SURMOUNT-1 showed substantial mean weight reductions at 72 weeks, establishing tirzepatide as one of the most effective evidence-based options in this category.
PubMed →FDA Approves First Treatment to Reduce Risk of Serious Heart Problems in Adults with Obesity or Overweight
FDA notes semaglutide is approved to reduce excess weight and maintain weight reduction long term in certain adults with obesity or overweight.
Full Text →Once-Weekly Semaglutide in Adults with Overweight or Obesity
STEP 1 demonstrated sustained clinically relevant weight reduction through 68 weeks, making semaglutide a foundational therapy in modern obesity care.
PubMed →Oxytocin as an Anti-obesity Treatment
Review of animal, primate, and human work suggesting oxytocin may reduce food intake and body weight, while also emphasizing that the human evidence base is still early.
PubMed →Evidence strength is not identical across all therapies. Some placements are supported by FDA labeling or landmark randomized trials, while others rely more heavily on mechanistic, adjunctive, or early-stage literature and should be framed accordingly.